This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Horizon Technology Finance Provides Investment Portfolio Update For Second Quarter 2013

FARMINGTON, Conn., July 9, 2013 (GLOBE NEWSWIRE) -- Horizon Technology Finance Corporation (Nasdaq:HRZN) ("Horizon"), a leading specialty finance company that provides secured loans to venture capital and private equity backed development-stage companies in the technology, life science, healthcare information and services, and clean-tech industries, today provided a portfolio update for the second quarter of 2013.

"Horizon successfully executed on its investment strategy during the second quarter, funding a total of $29.1 million in venture loans to seven new portfolio companies and three existing portfolio companies across its target markets," said Gerald A. Michaud, President of Horizon. "While a majority of the fundings occurred later in the quarter, a typical trend within our industry, we are pleased with our strong investment activity during the second quarter and first half of 2013. Going forward, we will maintain our focus on taking advantage of select market opportunities that meet management's underwriting and return criteria."

New Loans Funded

New loans funded during the second quarter of 2013 totaled approximately $29.1 million. During the second quarter of 2013, Horizon provided funding to the following new and existing portfolio companies:
  • $3.5 million to a new portfolio company, Inotek Pharmaceuticals Corporation, a developer of innovative drug candidates to address significant diseases of the eye, with a major focus on glaucoma.
  • $1.1 million to an existing portfolio company, Mitralign, Inc., a developer of an innovative catheter based technology for percutaneous treatment of mitral regurgitation.
  • $2.0 million to a new portfolio company, New Haven Pharmaceuticals, Inc., a developer of prescription pharmaceuticals that utilize currently marketed drugs or active pharmaceutical ingredients generally recognized as safe for use in therapeutic applications.
  • $3.0 million to a new portfolio company, NexPlanar, Inc., a developer of next generation chemical mechanical planarization (CMP) pads for the semiconductor device industry.
  • $1.0 million to an existing portfolio company, Raydiance, Inc., a developer of precision manufacturing solutions enabled by femtosecond laser technology.
  • $3.0 million to a new portfolio company, Rypos, Inc., a developer of intelligent emissions reduction solutions with its patented electrically self-regenerating filters and proprietary catalytic technologies.
  • $6.0 million to a new portfolio company, a developer of next generation, high performance enterprise storage appliances for data driven organizations.
  • $5.0 million to a new portfolio company, a provider of Carrier Ethernet solutions for the metro edge.
  • $3.0 million to an existing portfolio company, a developer of cloud solutions for secure enterprise mobile device and application management.
  • $1.5 million to a new portfolio company, a provider of cloud-based financial assurance and predictive analytics solutions for communications service providers.

Refinanced Principal Balances, Early Principal Payoffs, and Principal Payments Received

During the quarter ended June 30, 2013, Horizon had no refinanced principal balances and experienced early pay-offs of principal totaling $19.3 million, compared to no refinanced balances and no early pay-offs during the first quarter of 2013. During the quarter ended June 30, 2013, Horizon received principal payments on investments totaling $8.7 million compared to the quarter ended March 31, 2013, wherein Horizon received principal payments on investments totaling $10.0 million.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs